Address maternal mortality in low- and middle-income countries by supporting the safe and effective use of an innovative uterotonic.

Although there has been a substantial reduction of maternal mortality since 2000, over 800 women are dying each day from complications in pregnancy and childbirth. Sub-Saharan Africa and South Asia, account for 86% of maternal deaths worldwide. Postpartum haemorrhage (PPH) is the major source of maternal mortality and morbidity.

Carbetocin Ferring™ (heat-stable carbetocin) is a uterotonic that has been recommended by the WHO for the prevention of PPH in settings where oxytocin, the current standard of care, is not available or of insufficient quality. The product is particularly suited to environments with high temperatures and suboptimal cold chain, as it is the only injectable uterotonic that can remain stable in humid and hot climates. However, its use should be closely monitored as it causes potent and long-lasting uterine contractions, which can be dangerous for the unborn child if administered before childbirth.

In targeted low-and middle-income countries, there is a strong need for information and training of end-users, i.e., medical staff (midwives, obstetricians, nurses) and policy makers, to ensure safe and efficient use of the drug.

EpiLinks is developing a training package and information, communication education (IEC) resources for Carbetocin Ferring™, to be made available to ministries of health and professional organisations in African implementing countries. Resources are defined and developed through an interactive and iterative process, including recommendations from the relevant field assessors.

Client/Funder: Ferring Pharmaceuticals

Project duration: 2020-2021

Contact: Isabelle Delrieu